Skip to main content
. 2016 Nov 9;7(49):81341–81356. doi: 10.18632/oncotarget.13228

Figure 8. Dual blockade of PD-1 and LAG-3 inhibits the tumor growth of KRS-SCCs.

Figure 8

(A) KRS-SCC cells were injected into wt B6 recipients which were randomized into two groups. One group was treated with anti-PD-1 and anti-LAG-3 antibodies and another one was treated with PBS as control. Tumor volume was monitored in both control (closed circle, n = 8) and treated recipients (closed square, n = 8) for 16 days. Arrows indicated the injection of anti-PD-1 and anti-LAG-3 antibodies. (B) Tumor weight was measured at the end of the experiments from control (white bar, n = 8) or treated group (black bar, n = 8). (C) Percentage of CD45+ cell infiltration in the tumors isolated from control (white bar, n = 8) or treated group (black bar, n = 8). (D) Percentage of CD8+ T cells in total CD45+ infiltrating cells in the tumors isolated from control (white bar, n = 8) or treated group (black bar, n = 8). Statistical significance was calculated with Student's t-test (Graphpad Version 5.01) between two groups as indicated, ***P ≤ 0.001, **P ≤ 0.01. Representative data are shown from three independent experiments for all panels.